AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00338832 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Program for Activity, Leisure Skills, and Socialization (PALSS)
Description: PALSS sessions will focus on motivating participants to engage in leisure and social activity. Sessions will include interactive, structured activity that will be led by a therapist, as well as unstructured leisure activities, such as board games, cards, general socialization, and viewing a travel video. Social and communication skills will not be explicitly taught or practiced. All participants will attend 90-minute sessions weekly for the first 16 weeks, then biweekly for the remaining 8 weeks.
Study NCT01988532 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: Subject will only fill out a questionnaire
Study NCT02632279 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tryptophan (TRP) depletion
Description: TRP depletion will be accomplished by administering a TRP-low amino acid protein drink containing 100 g of gelatin powder. The protein mixture consists of 18 amino acids. According to Dutch law, TRP is considered a food supplement and is not registered as a medicine.
Study NCT02632279 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo treatment will consist of an identical amino acid protein drink containing 100 g of gelatin powder to which 1.21g TRP is added.
Study NCT02326961 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive Placebo
Study NCT02821182 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiotherapy
Description: In patients with metastatic melanoma, anti-PD-1 treatment will be combined with stereotactic body radiotherapy (SBRT).~A total dose of 24 Gy SBRT will be delivered in 3 fractions to one measurable lesion and fractions will be separated >48h and \<96h.
Study NCT01110954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD L 506
Description: Two different doses will be compared
Study NCT01110954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD L 506
Description: Two different doses will be compared
Study NCT03936543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Position change
Description: Different position during central line catheterization
Study NCT03936543 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional position
Description: Conventional position during central line catheterization
Study NCT01347450 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cocoa powder berverage, dark chocolate bar
Description: Sugar drink containing 30 g of cocoa powder and 50 g of a 65% dark chocolate, and the control group received 30 g of placebo drink containing 0 g of cocoa powder. Each drink was prepared by using 300 ml of water and 30 g of sugar, also were consumed twice each day: with breakfast and afternoon meal. during 7-d after the intervention started.
Study NCT01347450 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sugar drink containing 30 g of cocoa powder and 50 g of a 65% dark chocolate, and the control group received 30 g of placebo drink containing 0 g of cocoa powder. Each drink was prepared by using 300 ml of water and 30 g of sugar, also were consumed twice each day: with breakfast and afternoon meal. during 7-d after the intervention started.
Study NCT02417974 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant (FMT)
Description: Fecal Microbiota Transplant (FMT)
Study NCT02371109 — intervention group
Intervention type: OTHER
Intervention: selftaken versus clinically taken swabs
Study NCT03023475 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LigaSure endoscopic vessel harvesting
Description: The radial artery will be harvested endoscopically using the LigaSure system.
Study NCT03023475 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TLS2 endoscopic vessel harvesting
Description: The radial artery will be harvested endoscopically using the TLS2 system.
Study NCT00318110 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NST using MUD for metastatic renal cell carcinoma
Description: Preparative regimen:~Fludarabine 25 mg/m2 IV once a day x 5 days (-6,-5,-4,-3,-2) Melphalan 70 mg/m2 IV once a day x 2 days (-3,-2) Donor Stem Cell Infusion: Stem cells will be infused on day 0 GVHD prophylaxis: Tacrolimus and methotrexate 5 mg/m2 IV day 1, 3, 6 and 11
Study NCT02287272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF 5993 pMDI
Description: 4 inhalations of CHF 5993 pMDI (BDP/FF/GB 100/6/25 micrograms per actuation) giving a total dose of 400, 24, 100 micrograms of BDP, FF, GB
Study NCT02287272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cimetidine plus CHF5993 pMDI
Description: Cimetidine 800 milligrams twice daily for 6 days. On the fourth day, in addition, 4 inhalations of CHF5993 pMDI (BDP/FF/GB total dose 400/24/100 micrograms)
Study NCT03880071 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT+ACT
Description: - The experimental group (DBT+ ACT) will have: 25 therapy group sessions (1 sessions of 2 hours once a week) 25 individual interview sessions (1 sessions of 1 hour once a week) will receive 25 group sessions and 25 individual ones during 6 months.
Study NCT03880071 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: DBT
Description: The control group (DBT) will have:~50 therapy group sessions (1 session of 2h30 once a week) 50 individual interview sessions (1 sessions of 1 hour once a week)
Study NCT00760578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily, oral
Study NCT00760578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Once daily, oral
Study NCT00760578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSDC-0160 90 mg
Description: Once daily, oral
Study NCT00760578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSDC-0160 220 mg
Description: Once daily, oral
Study NCT01635413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo strength training classes
Study NCT01635413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo tai chi classes
Study NCT01635413 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Undergo stretching and relaxation classes
Study NCT01635413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01635413 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02322918 — intervention group
Intervention type: GENETIC
Intervention: Blood samples for whole genomic/transcriptomic sequencing
Description: Participant will receive one blood draw whereby two samples will be extracted. If the participant wishes to participate in the study but is fearful of needles, they may be given the option to provide a saliva sample. A retrospective medical chart review will be performed after participant is discharged from BCPP in order to obtain a full phenotype. Genotyping of BDNF and COMT will be performed. Protein levels of BDNF will be determined. The remaining blood or saliva samples will be stored over the long-term in a biorepository at the BC Mental Health and Addictions Research Institute. A retrospective medical chart review will be completed after the participant is discharged.
Study NCT00004978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant interleukin-2 (rIL-2)
Description: Recombinant interleukin-2 at a dose of 7.5 MIU given twice daily subcutaneously for 5 consecutive days every 8 weeks for at least 3 cycles.
Study NCT01033266 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CPET
Description: CPET will be done on patients with overlap syndrome before and after clinical CPAP treatment.
Study NCT03985449 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Uterine Fibroid Option Grid encounter patient decision aid (text only)
Description: The uterine fibroid Option Grid patient decision aid facilitates choice awareness and deliberation about treatment options when clinicians and patients discuss the management of uterine fibroids. The content is organized in a tabular format and is based on patients' frequently asked questions.
Study NCT03985449 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Uterine Fibroid Option Grid encounter patient decision aid (text + Pictures)
Description: The Picture Option Grid uses the same evidence as the text version while integrating images and simpler text, thus utilizing pictorial superiority to help patients better understand and remember information more easily compared to just using words.
Study NCT03985449 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Uterine Fibroid Option Grid encounter patient decision aid (online)
Description: Clinicians can click a link in the electronic health record that will lead them to the EBSCO Health website where they can click the treatment options relevant to the patient and generate a decision aid.
Study NCT04371991 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: blood test (serum samples) for biochemical examination
Study NCT03331419 — intervention group
Intervention type: BEHAVIORAL
Intervention: Exercise test
Description: 30 sec of knee squats followed by a six minute walk test repeated on consecutive days.
Study NCT00107445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EF5
Description: Given IV
Study NCT02064868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serelaxin
Description: 30 µg/kg/day IV infusion
Study NCT02064868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: This treatment can include but is not limited to intravenous and/or oral diuretics, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor antagonists, beta blockers and aldosterone receptor antagonists, etc.
Study NCT02064868 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard of Care
Description: This treatment can include but is not limited to intravenous and/or oral diuretics, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor antagonists, beta blockers and aldosterone receptor antagonists, etc.
Study NCT04443725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine , Sofosbuvir, daclatasvir
Description: Hydroxychloroquine (hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 14 days (dose reductions for weight \< 45 kg or GFR (glomerular filtration rate) \<50ml/min) alone; as provided by the MOHP protocol), Sofosbuvir 400 mg once daily for 14 days and daclatasvir 90 mg for 14 days.
Study NCT04443725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care treatment
Description: Hydroxychloroquine (hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 14 days (dose reductions for weight \< 45 kg or GFR (glomerular filtration rate) \<50ml/min) alone; as provided by the MOHP protocol),
Study NCT02632279 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Stimulator ON
Description: Participants will be tested while their stimulator is turned ON
Study NCT02632279 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulator ON
Description: Participants will be tested while their stimulator is turned ON
Study NCT04590365 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carrageenan nasal and throat spray
Description: Iota-carrageenan nasal and throat spray (verum Coldamaris plus i.e. Iota-Carrageenan 0.12% plus 0.04% Kappa-Carrageenan in 0.5% saline)
Study NCT04590365 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Saline nasal and throat spray
Description: Saline nasal and throat spray (placebo Coldamaris sine i.e. 0.5% saline)
Study NCT02632279 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Stimulator OFF
Description: Participans will be tested while their stimulator is turned OFF
Study NCT02632279 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulator OFF
Description: Participans will be tested while their stimulator is turned OFF
Study NCT02050776 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell transplantation
Description: bone marrow derived mononuclear cells are administered intrathecally and intramuscularly in limb girdle muscular dystrophy patients
Study NCT01501617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hair Stimulating Complex (HSC)
Description: Study preparation (experimental) of 0.8 mL will be injected intradermally at Baseline and Week 6.
Study NCT01501617 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dulbecco's Modified Eagle Medium, DMEM
Description: Study preparation (placebo comparator) of 0.8 mL will be injected intradermally at Baseline and Week 6.
Study NCT02300558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eleclazine
Description: Tablets administered orally
Study NCT02300558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eleclazine placebo
Description: Tablets administered orally
Study NCT01937793 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: effortful swallowing exercise
Description: voluntarily increases the posterior tongue base pushing effort while swallowing
Study NCT01937793 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mendelsohn swallowing exercise
Description: voluntarily increase the extent and duration of laryngeal elevation while swallowing
Study NCT00905762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gatifloxacin
Description: Gatifloxacin 0.3% one drop instilled into study eye at visit 2.
Study NCT00905762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin 0.5% one drop instilled into study eye at visit 2.
Study NCT00905762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besifloxacin
Description: Besifloxacin 0.6% one drop instilled into study eye at visit 2.
Study NCT00813865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afegostat tartrate
Study NCT02780635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile App + Mailed Materials for managing stress associated with PTSD
Description: PTSD Coach and PTSD Family Coach mobile apps plus mailed Couples Coach intervention materials and discussion board added to PTSD Family Coach app
Study NCT02780635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile App for managing stress associated with PTSD
Description: PTSD Coach and PTSD Family Coach mobile apps
Study NCT02780635 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile App for managing stress associated with PTSD
Description: PTSD Coach and PTSD Family Coach mobile apps
Study NCT02660450 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prescription for Workload
Description: Prescription from 65% VO2max for 5 min of exercise
Study NCT02660450 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prescription for Heart Rate
Description: Prescription from 60 - 65% Maximum Heart Rate for 5 min of exercise
Study NCT02660450 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prescription Self Selected
Description: Prescription Self Selected from Perceived exertion at 3 - 4 (moderate) for 5 min of exercise
Study NCT03910738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection
Description: Active treatment (Nebido® Testosterone Undecanoate ) will be injected at Baseline, at week 6 and then every 12 weeks (Week 18, 30, 42 and 54)
Study NCT03910738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 4 mL Solution for Injection
Description: Placebo will be injected at Baseline, at week 6 and then every 12 weeks (Week 18, 30, 42 and 54)
Study NCT03910738 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: MRI
Description: Conventional MS sequences (OFSEP recommendations) and unconventional MRI sequences (Baseline, week 30 and 66)
Study NCT03910738 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Conventional MS sequences (OFSEP recommendations) and unconventional MRI sequences (Baseline, week 30 and 66)
Study NCT03910738 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities
Description: BICAMS; SF-36 and EQ-5D-3L; MFIS; HADS; WPAI:MS (at baseline, week 30 and 66)
Study NCT03910738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities
Description: BICAMS; SF-36 and EQ-5D-3L; MFIS; HADS; WPAI:MS (at baseline, week 30 and 66)
Study NCT03910738 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Assessment of disability
Description: EDSS (Baseline, week 30 and 66)
Study NCT03910738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of disability
Description: EDSS (Baseline, week 30 and 66)
Study NCT03505788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: In the experimental group, the patient will receive the standard of care loop diuretics and acetazolamide
Study NCT03505788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the placebo group, the patient will receive the standard of care loop diuretics and the placebo
Study NCT00613002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone gel
Description: once daily transdermal testosterone gel, 300 mcg
Study NCT00613002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: once daily transdermal placebo gel
Study NCT00998413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Description: multifaceted family-based, physical exercise, nutrition, and behavioural intervention study for 18 month, in children aged 6-16 years with asthma and overweight/obesity.
Study NCT01887275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: medical ozone therapy with humares
Description: Medical ozone therapy with instrument made in Germany Patients in this group will receive autohemotherapy treatment. First month: ozone concentration: 20µg \~40µg /ml;The second month: 30µg/ml × 100ml oxygen- ozone gas × 100 ml blood;The third month: 20µg/ml × 100ml oxygen- ozone gas× 100 ml blood.
Study NCT01887275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional interferon-α
Description: Patients in the conventional interferon-α treatment group received subcutaneouslly injection of 5 million units of conventional interferon-α in three times per week for at least 24 weeks.
Study NCT03871439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304 Formulation A
Description: 50mg
Study NCT03871439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304 Formulation B
Description: 50mg
Study NCT02226159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Study NCT02226159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine with Dexamethasone
Study NCT02113826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib 800mg qd daily for 4 weeks = 1 cycle
Study NCT04955483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Virtual single energy combined with MAR reconstruction group
Description: combined with MAR reconstruction group
Study NCT02833753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Intraperitoneal oxaliplatin will be given along with standard chemotherapy FOLFIRI.~Level 1: Oxaliplatin 25mg/m2 IP every 2 weeks on day #1 of chemotherapy . Level 2: Oxaliplatin 55mg/m2 IP every 2 weeks on day #1 of chemotherapy Level 3: Oxaliplatin 85mg/m2 IP every 2 weeks on day #1 of chemotherapy Level 4: Oxaliplatin 55 mg/m2 IP every 2 weeks on day #1 of chemotherapy (due to DLTs found)
Study NCT02307097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioural Bibliotherapy
Study NCT02307097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioural Therapy
Study NCT02307097 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WAIT
Study NCT03579472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp Alfa
Description: Given IV
Study NCT03579472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Given IV
Study NCT01714206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin 0.5 mg
Description: Two 0.25 mg tablets (0.5 mg total dose) taken orally (by mouth) on Day 1.
Study NCT01714206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin 0.5 mg
Description: Two 0.25 mg tablets (0.5 mg total dose) taken orally (by mouth) on Day 1.
Study NCT01714206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin 0.25 mg
Description: One 0.25 mg tablet taken orally on Days 2 through 7.
Study NCT01714206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin 0.25 mg
Description: One 0.25 mg tablet taken orally on Days 2 through 7.